Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Altimmune Analyst Ratings
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Optimistic Buy Rating for Altimmune's Pemvidutide on Promising Clinical and Strategic Developments
Altimmune Analyst Ratings
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
Evercore ISI Remains a Buy on Altimmune (ALT)
Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Announces Target Price $20
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Piper Sandler Maintains Overweight on Altimmune, Maintains $25 Price Target